The DOI matches its Crossref record.
Emergence of Quinolone-Resistant Escherichia coli Bacteremia in Neutropenic Patients with Cancer Who Have Received Prophylactic Norfloxacin
Abstract
Between January 1988 and December 1992, 35 episodes of Escherichia coli bacteremia were identified in a series of 230 cases of bacteremia in neutropenic patients with cancer. Thirteen episodes (37%) were due to quinolone-resistant strains. Minimal inhibitory concentrations of norfloxacin ranged from 16 micrograms/mL to 128 micrograms/mL, and those of ciprofloxacin from 8 micrograms/mL to 64 micrograms/mL. The incidence of bacteremia due to quinolone-resistant E. coli increased from zero episodes per 1,000 hospital admissions in 1988 to four episodes per 1,000 admissions in 1992 (P = .018). To identify risk factors for quinolone-resistant E. coli bacteremia, we compared episodes of quinolone-resistant and quinolone-susceptible E. coli bacteremia. Among the variables analyzed, prophylaxis with norfloxacin was the only factor significantly associated with the development of quinolone-resistant E. coli bacteremia; 13 of 13 patients with bacteremia due to resistant strains received norfloxacin, whereas only one (5%) of 22 patients with bacteremia due to susceptible strains did (P < .001). According to our data, neutropenic patients with cancer who receive fluoroquinolone prophylaxis may be at risk of developing E. coli bacteremia due to quinolone-resistant strains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R., Pizzo, P., Rolston, K. V. I., Shenep, J. L., & Young, L. S. (1997) · Clinical Infectious Diseases · doi:10.1086/513764 · Cited by 672
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M. S., Martinelli, G., Allione, B., D'Antonio, D., Buelli, M., Nosari, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044097 · Cited by 648
Emergence and Dissemination of Quinolone-Resistant Escherichia coli in the Community
Garau, J., Xercavins, M., Rodríguez-Carballeira, M., Gómez-Vera, J. R., Coll, I., Vidal, D., Llovet, T., & Ruíz-Bremón, A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2736 · Cited by 337
Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis.
Engels, E. A., Lau, J., & Barza, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1179 · Cited by 256
Metadata
- Authors
- Carratala, J., Fernandez-Sevilla, A., Tubau, F., Callis, M., & Gudiol, F.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-03-01
- Volume
- 20
- Issue
- 3
- Pages
- 557-560
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2055472783
- Cited by
- 177
- References
- 0
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emergence of Quinolone-Resistant Escherichia coli Bacteremia in Neutropenic Patients with Cancer Who Have Received Prophylactic Norfloxacin. https://app.cochat.ai/papers/10.1093/clinids/20.3.557
- The paper
- Carratala, J., Fernandez-Sevilla, A., Tubau, F., Callis, M., & Gudiol, F. (1995). Emergence of Quinolone-Resistant Escherichia coli Bacteremia in Neutropenic Patients with Cancer Who Have Received Prophylactic Norfloxacin. Clinical Infectious Diseases. https://doi.org/10.1093/clinids/20.3.557
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.